508 related articles for article (PubMed ID: 31775767)
21. Implications of bilateral free trade agreements on access to medicines.
Correa CM
Bull World Health Organ; 2006 May; 84(5):399-404. PubMed ID: 16710551
[TBL] [Abstract][Full Text] [Related]
22. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
[TBL] [Abstract][Full Text] [Related]
23. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications.
Baxi SM; Beall R; Yang J; Mackey TK
Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850
[TBL] [Abstract][Full Text] [Related]
24. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
Gleeson D; Lopert R; Reid P
Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
[TBL] [Abstract][Full Text] [Related]
25. Trade agreements and the risks for the nursing workforce, nursing practice and public health: A scoping review.
Kidgell D; Hills D; Griffiths D; Endacott R
Int J Nurs Stud; 2020 Sep; 109():103676. PubMed ID: 32603925
[TBL] [Abstract][Full Text] [Related]
26. The Trans-Pacific Partnership and pharmaceutical innovation.
Freeman RA
Res Social Adm Pharm; 2016; 12(4):633-7. PubMed ID: 26803645
[TBL] [Abstract][Full Text] [Related]
27. Protecting the autonomy of states to enact tobacco control measures under trade and investment agreements.
Mitchell A; Sheargold E
Tob Control; 2015 Jun; 24(e2):e147-53. PubMed ID: 25361743
[TBL] [Abstract][Full Text] [Related]
28. Is health impact assessment useful in the context of trade negotiations? A case study of the Trans Pacific Partnership Agreement.
Hirono K; Haigh F; Gleeson D; Harris P; Thow AM; Friel S
BMJ Open; 2016 Apr; 6(4):e010339. PubMed ID: 27044579
[TBL] [Abstract][Full Text] [Related]
29. Defending access to medicines in regional trade agreements: lessons from the Regional Comprehensive Economic Partnership - a qualitative study of policy actors' views.
Townsend B
Global Health; 2021 Jul; 17(1):78. PubMed ID: 34238347
[TBL] [Abstract][Full Text] [Related]
30. A new generation of trade policy: potential risks to diet-related health from the trans pacific partnership agreement.
Friel S; Gleeson D; Thow AM; Labonte R; Stuckler D; Kay A; Snowdon W
Global Health; 2013 Oct; 9():46. PubMed ID: 24131595
[TBL] [Abstract][Full Text] [Related]
31. Advancing Public Health on the Changing Global Trade and Investment Agenda Comment on "The Trans-Pacific Partnership: Is It Everything We Feared for Health?".
Thow AM; Gleeson D
Int J Health Policy Manag; 2017 May; 6(5):295-298. PubMed ID: 28812819
[TBL] [Abstract][Full Text] [Related]
32. Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad.
Luo J; Kesselheim AS
AMA J Ethics; 2016 Jul; 18(7):727-35. PubMed ID: 27437823
[TBL] [Abstract][Full Text] [Related]
33. Evolving trade policy and the Trans-Pacific Partnership Agreement: does it threaten Vietnam's access to medicine and its progress towards scaling up HIV prevention, treatment and care?
Linh NN; Huong NT; Thuy HT
Glob Public Health; 2015; 10 Supppl 1():S149-60. PubMed ID: 25469870
[TBL] [Abstract][Full Text] [Related]
34. The Trans-Pacific Partnership Agreement: Trading away our health?
Ruckert A; Schram A; Labonté R
Can J Public Health; 2015 Apr; 106(4):e249-51. PubMed ID: 26285198
[TBL] [Abstract][Full Text] [Related]
35. Alcohol labelling rules in free trade agreements: Advancing the industry's interests at the expense of the public's health.
Gleeson D; O'Brien P
Drug Alcohol Rev; 2021 Jan; 40(1):31-40. PubMed ID: 32239601
[TBL] [Abstract][Full Text] [Related]
36. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand.
Supakankunti S; Janjaroen WS; Tangphao O; Ratanawijitrasin S; Kraipornsak P; Pradithavanij P
Bull World Health Organ; 2001; 79(5):461-70. PubMed ID: 11417042
[TBL] [Abstract][Full Text] [Related]
37. The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement.
Motari M; Nikiema JB; Kasilo OMJ; Kniazkov S; Loua A; Sougou A; Tumusiime P
BMC Public Health; 2021 Mar; 21(1):490. PubMed ID: 33706726
[TBL] [Abstract][Full Text] [Related]
38. TPPA and tobacco control: threats to APEC countries.
Sy DK; Stumberg RK
Tob Control; 2014 Nov; 23(6):466-70. PubMed ID: 25170023
[TBL] [Abstract][Full Text] [Related]
39. Access to generic antiretrovirals: inequality, intellectual property law, and international trade agreements.
Castro A; Westerhaus M
Cad Saude Publica; 2007; 23 Suppl 1():S85-96. PubMed ID: 17308722
[TBL] [Abstract][Full Text] [Related]
40. TRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines?
Kerry VB; Lee K
Global Health; 2007 May; 3():3. PubMed ID: 17524147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
